About the Company
We do not have any company description for ANAVEX LIFE SCIENCES CORP. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on ANAVEX LIFE SCIENCES CORP.
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on ...
Anavex Life Sciences Corp. to Announce Fiscal Year 2024 ... - Nasdaq
Anavex Life Sciences Corp. announced that it will release its financial results for the fiscal year ended September 30, 2024, on December 23, 2024, and will host a conference call at 8:30 am ET ...
Anavex Life Sciences Corp. Announces Financial Results ... - Nasdaq
Anavex Life Sciences Corp., a biopharmaceutical company focused on treatments for neurological disorders, will release its financial results for the first fiscal quarter on February 12, 2025.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Expected To Breakeven In ...
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Is Anavex LIfe Sciences Corp. a Stock Worth Buying?
Anavex Life Sciences Corp. 's media department has been busy lately touting the potential benefits of Alzheimer's disease drugs in its pipeline, but the company's research is in the uber-early stages.
Why Anavex Life Sciences Corp. Rocketed Higher Today
Tiny biotech Anavex Life Sciences (AVXL -3.80%) got a little bigger today after announcing that Biogen (BIIB 2.60%) will test the company's lead drug candidate, ANAVEX 2-73, in a preclinical assay.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript August 12, 2025 Anavex Life Sciences Corp. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.13. Clint Tomlinson: Good morning, and ...
Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months
Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule ...
19,558 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by ...
Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44. The business’s 50 day moving average is $9.48 and its 200-day moving average is $7.99.
Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.
Not a big deal Anavex Life Sciences has sponsored one mid-stage trial with its only clinical-stage candidate, 2-73 for treatment of Alzheimer's disease,and its market cap of just $138 million at ...
Why Anavex Life Sciences Corp. Just Imploded - The Motley Fool
What: Shares of Anavex Life Sciences (AVXL -0.84%), a clinical-stage biotech company focused on the development of drug candidates to treat Alzheimer's disease and other central nervous system ...
Similar Companies
Loading the latest forecasts...